Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.585 -0.115 (-6.76%)

Streaming Delayed Price Updated: 1:29 PM EDT, Apr 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

September 07, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying ↗

August 08, 2022

Although US stocks closed mixed on Friday, there were a few notable insider trades.

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: Aldeyra Therapeutics Q2 Earnings ↗

August 05, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial ↗

July 12, 2022

Via Benzinga

Why Aldeyra Therapeutics' Shares Are Soaring Today? ↗

June 08, 2022

Via Benzinga

Aldeyra Therapeutics: Q1 Earnings Insights ↗

May 05, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights

August 05, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For August 5, 2022 ↗

August 05, 2022

Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.

Via Benzinga

Earnings Outlook For Aldeyra Therapeutics ↗

August 04, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Aldeyra...

Via Benzinga

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

July 29, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 12, 2022

Via Benzinga

The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner ↗

July 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗

July 13, 2022

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 12, 2022

Via Benzinga

Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial

July 12, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap

July 11, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

June 09, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease

June 08, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease

June 07, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease

May 24, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference

May 23, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness ↗

May 18, 2022

Via Benzinga

Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness

May 18, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights

May 05, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting

May 04, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

70 Biggest Movers From Friday ↗

May 02, 2022

Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 29, 2022

Via Benzinga

48 Stocks Moving In Friday's Mid-Day Session ↗

April 29, 2022

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

All News about Aldeyra Therapeutics, Inc. - Common Stock